Literature DB >> 2849664

Dose selective dissociation of water and solute excretion after renal alpha-2 adrenoceptor stimulation.

D E Blandford1, D D Smyth.   

Abstract

In vitro studies have demonstrated an antagonism of the renal effects of vasopressin after alpha-2 adrenoceptor stimulation. Whether the effect of alpha-2 adrenoceptor stimulation in relation to sodium and water excretion in vivo is mediated through independent mechanisms is unclear. The dose-response relationship between renal alpha-2 adrenoceptor stimulation (clonidine) and water and electrolyte excretion was evaluated in anesthetized rats. Rats were nephrectomized unilaterally 7 to 10 days before the experimental day to allow isolation of renal function. A base-line level of sodium and water excretion was established by the infusion of saline (0.097 ml/min i.v.). In separate groups of rats, clonidine was infused directly into the renal artery at 0 (vehicle), 0.1, 0.3, 1 or 3 micrograms/kg/min at 0.0034 ml/min. The lower doses (0.1, 0.3 and 1 microgram/kg/min) produced a dose-related increase in urine volume and free water clearance and a decrease in urine osmolality. Electrolyte or solute excretion was not altered at these infusion rates even though urine volume increased 4-fold. The highest dose investigated (3 micrograms/kg/min) increased urine volume (9-fold) and sodium excretion (4-fold). Free water clearance and osmolar clearance were also increased. The effects of clonidine were attenuated by yohimbine but not prazosin indicating these effects were mediated by alpha-2 adrenoceptor stimulation. These results demonstrate a dose-related selectivity of alpha-2 adrenoceptor stimulation for water and sodium excretion. The increase in water excretion at the lower infusion rates would be consistent with the antagonism of the renal effects of vasopressin. The potent natriuresis observed only at higher doses indicates another mechanism may be involved.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2849664

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  9 in total

1.  Clonidine-induced increase in osmolar clearance and free water clearance via activation of two distinct alpha 2-adrenoceptor sites.

Authors:  H D Intengan; D D Smyth
Journal:  Br J Pharmacol       Date:  1996-10       Impact factor: 8.739

2.  Diuretic effects of medetomidine compared with xylazine in healthy dogs.

Authors:  Md Hasanuzzaman Talukder; Yoshiaki Hikasa
Journal:  Can J Vet Res       Date:  2009-07       Impact factor: 1.310

3.  Antagonistic effects of atipamezole, yohimbine, and prazosin on xylazine-induced diuresis in clinically normal cats.

Authors:  Yusuke Murahata; Yuya Miki; Yoshiaki Hikasa
Journal:  Can J Vet Res       Date:  2014-10       Impact factor: 1.310

4.  Attenuated renal response to moxonidine and rilmenidine in one kidney-one clip hypertensive rats.

Authors:  P Li; S B Penner; D D Smyth
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

5.  Antagonism by idazoxan at low dose but not high dose, of the natriuretic action of moxonidine.

Authors:  D R Allan; S B Penner; D D Smyth
Journal:  Br J Pharmacol       Date:  1996-01       Impact factor: 8.739

6.  Renal imidazoline preferring sites and solute excretion in the rat.

Authors:  D R Allan; S B Penner; D D Smyth
Journal:  Br J Pharmacol       Date:  1993-04       Impact factor: 8.739

7.  Central and renal I1 imidazoline preferring receptors: two unique sites mediating natriuresis in the rat.

Authors:  S B Penner; D D Smyth
Journal:  Cardiovasc Drugs Ther       Date:  1994-03       Impact factor: 3.727

8.  Sodium excretion following central administration of an I1 imidazoline receptor agonist, moxonidine.

Authors:  S B Penner; D D Smyth
Journal:  Br J Pharmacol       Date:  1994-08       Impact factor: 8.739

9.  Antagonistic effects of atipamezole, yohimbine and prazosin on medetomidine-induced diuresis in healthy cats.

Authors:  Yusuke Murahata; Asami Yamamoto; Yuya Miki; Yoshiaki Hikasa
Journal:  J Vet Med Sci       Date:  2013-10-08       Impact factor: 1.267

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.